Petr Widimsky

List of Publications by Year
in descending order

310 papers	60,999 citations	9756 73 h-index	871 243 g-index
321 all docs	321 docs citations	321 times ranked	39598 citing authors

#	Article	IF	Citations
1	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	1.0	7,100
2	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	1.0	5,034
3	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
4	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
5	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
6	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	1.0	2,649
7	Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29, 2276-2315.	1.0	2,645
8	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	1.0	2,305
9	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal, 2008, 29, 2909-2945.	1.0	2,128
10	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€¡. European Journal of Heart Failure, 2008, 10, 933-989.	2.9	1,893
11	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, The, 2011, 377, 1409-1420.	6.3	1,759
12	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	13.9	1,745
13	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	1.0	1,617
14	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	0.7	1,360
15	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 rgBT /Ov	3.7	1,[illegible]
16	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2165-2175.	13.9	748
17	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Heart Journal, 2009, 30, 2769-2812.	1.0	735
18	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	6.3	725

#	Article	IF	Citations
19	Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 2908.	3.8	717
20	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine, 2012, 366, 20-33.	13.9	701
21	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	13.9	695
22	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 930-942.	13.9	681
23	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2205-2217.	13.9	596
24	Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine, 2009, 361, 2330-2341.	13.9	560
25	Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. European Heart Journal, 2010, 31, 943-957.	1.0	548
26	Pretreatment with Prasugrel in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine, 2013, 369, 999-1010.	13.9	539
27	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. New England Journal of Medicine, 2015, 372, 1389-1398.	13.9	536
28	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0 rgBT /Overlock 10 T	3.1	5[illegible]
29	Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 3122-3135.	1.2	349
30	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2011, 32, 1854-1864.	1.0	343
31	Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 51, 2028-2033.	1.2	314
32	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology, 2019, 157, 682-691.e2.	0.6	299
33	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.	0.7	297
34	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	1.0	275
35	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	0.7	263
36	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine, 2019, 381, 1309-1320.	13.9	255

#	Article	IF	Citations
37	One-Year Coronary Bypass Graft Patency. Circulation, 2004, 110, 3418-3423.	1.6	243
38	Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2009, 301, 1779.	3.8	238
39	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. European Heart Journal, 2013, 34, 2149-2157.	1.0	225
40	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	1.2	224
41	Off-pump versus on-pump coronary surgery: final results from a prospective randomized study Prague-4. Annals of Thoracic Surgery, 2004, 77, 789-793.	0.7	184
42	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. Hypertension, 2015, 65, 407-413.	1.3	178
43	Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Circulation, 2016, 134, 1603-1612.	1.6	167
44	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. JAMA - Journal of the American Medical Association, 2010, 304, 1339-1349.	3.8	161
45	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	2.9	152
46	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent inÂST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. JACC: Cardiovascular Interventions, 2015, 8, 189-197.	1.1	145
47	Design and rationale of CURRENT-OASIS 7: A randomized, 2 Ã— 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and nonâ€“ST-elevation acute coronary syndromes managed with an early invasive strategy. American Heart Journal, 2008, 156, 1080-1088.e1.	1.2	140
48	1-Year Outcomes of Patients UndergoingÂPrimary Angioplasty for Myocardial Infarction Treated With Prasugrel VersusÂTicagrelor. Journal of the American College of Cardiology, 2018, 71, 371-381.	1.2	139
49	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
50	Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. European Heart Journal, 2008, 29, 1495-1503.	1.0	132
51	Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. European Heart Journal, 2009, 30, 2019-2028.	1.0	130
52	Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry. Critical Care, 2011, 15, R291.	2.5	124
53	Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet, The, 2009, 374, 787-795.	6.3	123
54	Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. European Heart Journal, 2014, 35, 787-794.	1.0	120

#	Article	IF	Citations
55	Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume. JACC: Cardiovascular Interventions, 2013, 6, 258-266.	1.1	117
56	Primary angioplasty in acute myocardial infarction with right bundle branch block: should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy?. European Heart Journal, 2012, 33, 86-95.	1.0	115
57	4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1-14.	1.2	114
58	Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. European Heart Journal, 2012, 33, 2644-2652.	1.0	113
59	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, 157, 403-412.e5.	0.6	108
60	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	6.3	105
61	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	0.7	105
62	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. Circulation, 2008, 118, 2038-2046.	1.6	98
63	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	1.6	96
64	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology, 2019, 73, 3271-3280.	1.2	95
65	Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 1853-1859.	1.2	89
66	Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial. European Heart Journal, 2007, 28, 679-684.	1.0	88
67	Intracoronary Injection of Autologous Bone Marrow-Derived Mononuclear Cells in Patients With Large Anterior Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 49, 2373-2374.	1.2	87
68	How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?. European Heart Journal, 2011, 32, 396-403.	1.0	85
69	Routine immediate extubation for off-pump coronary artery bypass grafting without thoracic epidural analgesia. Annals of Thoracic Surgery, 2002, 74, 1544-1547.	0.7	82
70	Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2013, 6, 357-368.	1.1	81
71	â€œStent 4 Lifeâ€•Targeting PCI at all who will benefit the most. EuroIntervention, 2009, 4, 555-557.	1.4	80
72	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	1.0	79

#	Article	IF	Citations
73	Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 187.	1.5	78
74	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
75	Severe Left Ventricular Dyssynchrony Is Associated With Poor Prognosis in Patients With Moderate Systolic Heart Failure Undergoing Coronary Artery Bypass Grafting. Journal of the American College of Cardiology, 2007, 50, 1315-1323.	1.2	74
76	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. Hypertension, 2016, 67, 397-403.	1.3	73
77	Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention. Journal of the American College of Cardiology, 2014, 63, 954-963.	1.2	70
78	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology, 2019, 73, 121-130.	1.2	69
79	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. Journal of the American College of Cardiology, 2009, 54, 468-476.	1.2	67
80	Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 180.	1.5	66
81	Shock Index: A Simple Clinical Parameter for Quick Mortality Risk Assessment in Acute Myocardial Infarction. Canadian Journal of Cardiology, 2011, 27, 739-742.	0.8	66
82	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	0.7	65
83	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2563-2571.	1.2	64
84	Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. European Heart Journal, 2010, 31, 1708-1716.	1.0	63
85	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	1.6	63
86	Eligibility for Renal Denervation. Hypertension, 2014, 63, 1319-1325.	1.3	61
87	Early Tissue Distribution of Bone Marrow Mononuclear Cells After Transcoronary Transplantation in a Patient With Acute Myocardial Infarction. Circulation, 2005, 112, e63-5.	1.6	59
88	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. JACC: Cardiovascular Interventions, 2009, 2, 909-916.	1.1	59
89	Long-term survival following acute heart failure: The Acute Heart Failure Database Main registry (AHEAD Main). European Journal of Internal Medicine, 2013, 24, 151-160.	1.0	59
90	AHEAD score â€" Long-term risk classification in acute heart failure. International Journal of Cardiology, 2016, 202, 21-26.	0.8	59

#	Article	IF	Citations
91	Anticoagulation With Otamixaban and Ischemic Events in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2013, 310, 1145.	3.8	58
92	A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2010, 75, 158-166.	0.7	55
93	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 152-167.	1.4	50
94	Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). American Heart Journal, 2017, 183, 108-114.	1.2	49
95	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	1.0	49
96	The incidence, treatment strategies and outcomes of acute coronary syndromes in the â€œreperfusion networkâ€•of different hospital types in the Czech Republic: Results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. International Journal of Cardiology, 2007, 119, 212-219.	0.8	48
97	The additional value of patient-reported health status in predicting 1-year mortality after invasive coronary procedures: a report from the Euro Heart Survey on Coronary Revascularisation. Heart, 2007, 93, 339-344.	1.2	47
98	Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. American Heart Journal, 2011, 161, 254-260.e4.	1.2	46
99	Radial versus femoral access for elderly patients with acute coronary syndrome undergoing coronary angiography and intervention: insights from the RIVAL trial. American Heart Journal, 2015, 170, 880-886.	1.2	46
100	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 229-243.	1.4	46
101	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 171-180.	1.4	46
102	Implementation of primary angioplasty in Europe: Stent for Life initiative progress report. EuroIntervention, 2012, 8, 35-42.	1.4	45
103	Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 396, 830-838.	6.3	44
104	One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry. EuroIntervention, 2012, 7, 1181-1188.	1.4	44
105	Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Cardiac Care, 2011, 13, 116-122.	0.2	43
106	Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: Results from the prospective randomized trial PRAGUE 11â€“Coronary Artery Bypass and REactivity of Thrombocytes (CABARET). Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 1054-1060.	0.4	42
107	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	1.2	42
108	Prognostic Value of TNF-Related Apoptosis Inducing Ligand (TRAIL) in Acute Coronary Syndrome Patients. PLoS ONE, 2013, 8, e53860.	1.1	41

#	Article	IF	Citations
109	Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 363-372.	0.4	38
110	Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IVâ€“ACS. American Heart Journal, 2004, 147, 865-873.	1.2	37
111	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 203-212.	1.1	37
112	Next Day Discharge After Successful Primary Angioplasty for Acute ST Elevation Myocardial Infarction An Open Randomized Study "Prague-5". International Heart Journal, 2008, 49, 653-659.	0.5	36
113	High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration. American Heart Journal, 2011, 161, 500-507.e1.	1.2	36
114	Reperfusion therapy of acute ischaemic stroke and acute myocardial infarction: similarities and differences. European Heart Journal, 2014, 35, 147-155.	1.0	36
115	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation, 2019, 140, 1451-1459.	1.6	36
116	Both selective and nonselective His bundle, but not myocardial, pacing preserve ventricular electrical synchrony assessed by ultra-high-frequency ECG. Heart Rhythm, 2020, 17, 607-614.	0.3	36
117	Uric acid, allopurinol therapy, and mortality in patients with acute heart failureâ€”results of the Acute HEart FAilure Database registry. Journal of Critical Care, 2012, 27, 737.e11-737.e24.	1.0	34
118	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	1.1	34
119	Pericardial Involvement During the Course of Myocardial Infarction. Chest, 1995, 108, 89-93.	0.4	32
120	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. Heart, 2013, 99, 626-633.	1.2	31
121	Randomized comparison of endothelial progenitor cells capture stent versus cobaltâ€chromium stent for treatment of STâ€elevation myocardial infarction. Sixâ€month clinical, angiographic, and IVUS followâ€up. Catheterization and Cardiovascular Interventions, 2010, 76, 627-631.	0.7	29
122	The incidence and outcomes of acute coronary syndromes in a central European country: Results of the CZECH-2 registry. International Journal of Cardiology, 2014, 173, 204-208.	0.8	29
123	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. American Heart Journal, 2009, 157, 763-770.	1.2	28
124	Platelet glycoprotein GP VI 13254C allele is an independent risk factor of premature myocardial infarction. Thrombosis Research, 2010, 125, e61-e64.	0.8	28
125	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology, 2020, 27, 296-307.	0.8	28
126	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	1.6	27

#	Article	IF	Citations
127	Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 183-192.	0.9	26
128	Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking â€œParadoxâ€• Journal of Cardiovascular Pharmacology, 2009, 53, 368-372.	0.8	25
129	Performance of the resolute zotarolimusâ€•eluting stent in small vessels. Catheterization and Cardiovascular Interventions, 2014, 84, 17-23.	0.7	25
130	Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients With Ongoing Cardiogenic Shock. Critical Care Medicine, 2014, 42, 281-288.	0.4	25
131	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. Journal of Hypertension, 2017, 35, 1093-1099.	0.3	25
132	Impact of Access Site on Bleeding andÂIschemic Events in Patients With Nonâ€“ST-Segment Elevation Myocardial Infarction Treated With Prasugrel. JACC: Cardiovascular Interventions, 2016, 9, 897-907.	1.1	24
133	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€•based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	2.9	24
134	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with nonâ€“ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal, 2011, 161, 650-656.e1.	1.2	23
135	Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 Study. Heart Rhythm, 2019, 16, 1334-1340.	0.3	23
136	Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: A genetic substudy of the PRAGUE-8 trial. Atherosclerosis, 2010, 212, 548-552.	0.4	22
137	Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis. JACC: Cardiovascular Interventions, 2013, 6, 905-913.	1.1	21
138	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. European Heart Journal, 2018, 39, 1567-1573.	1.0	21
139	Prevalence of stress-induced myocardial stunning (Tako-Tsubo cardiomyopathy) among patients undergoing emergency coronary angiography for suspected acute myocardial infarction. International Journal of Cardiology, 2007, 120, 411-413.	0.8	20
140	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. International Journal of Cardiology, 2016, 214, 483-484.	0.8	20
141	Prediction of shortâ€•and longâ€•term mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	2.9	20
142	Feasibility and safety of direct catheter-based thrombectomy in the treatment of acute ischaemic stroke. Cooperation among cardiologists, neurologists and radiologists. Prospective registry PRAGUE-16. EuroIntervention, 2017, 13, 131-136.	1.4	20
143	Stent for Life: how this initiative began?. EuroIntervention, 2012, 8, P8-P10.	1.4	20
144	Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 429-436.	0.2	20

#	Article	IF	Citations
145	Myocardial positive pre-ejection velocity accurately detects presence of viable myocardium, predicts recovery of left ventricular function and bears a prognostic value after surgical revascularization. European Heart Journal, 2007, 28, 1366-1373.	1.0	19
146	Transfer Times and Outcomes in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Interhospital Transfer for Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 437-444.	0.9	19
147	REVIEW: Stent Thrombosisâ€”Risk Assessment and Prevention. Cardiovascular Therapeutics, 2010, 28, e92-100.	1.1	18
148	Radial versus femoral access, bleeding and ischemic events in patients with nonâ€“ST-segment elevation acute coronary syndrome managed with an invasive strategy. American Heart Journal, 2013, 165, 583-590.e1.	1.2	18
149	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. International Journal of Cardiology, 2013, 168, 2510-2517.	0.8	18
150	Positive Influence of Being Overweight/Obese on Long Term Survival in Patients Hospitalised Due to Acute Heart Failure. PLoS ONE, 2015, 10, e0117142.	1.1	18
151	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 198-213.	1.4	18
152	Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention. European Heart Journal, 2021, 42, 298-307.	1.0	18
153	Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. EuroIntervention, 2016, 12, 23-29.	1.4	18
154	Renal disease and acute coronary syndrome. Heart, 2010, 96, 86-92.	1.2	17
155	High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel. Journal of Thrombosis and Thrombolysis, 2012, 33, 349-354.	1.0	17
156	Usefulness and Safety of Vorapaxar in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). American Journal of Cardiology, 2014, 114, 665-673.	0.7	17
157	Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Nonâ€“ST-Elevation Myocardial Infarction (ACCOAST) study. American Heart Journal, 2015, 170, 1025-1032.e2.	1.2	17
158	Direct Catheter-Based Thrombectomy for Acute Ischemic Stroke. Journal of the American College of Cardiology, 2015, 66, 487-488.	1.2	17
159	MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. Journal of Personalized Medicine, 2021, 11, 508.	1.1	17
160	Electrocardiographic changes can precede the development of myocardial hypertrophy in the setting of hypertrophic cardiomyopathy. International Journal of Cardiology, 1989, 23, 335-341.	0.8	16
161	Reimplantation of anomalous right coronary artery arising from the pulmonary trunk leading to normal coronary flow reserve late after surgery. Annals of Thoracic Surgery, 2003, 76, 1287-1289.	0.7	16
162	Diurnal Variation of Soluble E- and P-Selectin, and Intercellular Adhesion Molecule-1 in Patients with and without Coronary Artery Disease. Cardiology, 2004, 102, 194-199.	0.6	16

#	Article	IF	Citations
163	ORIGINAL RESEARCHâ€"PHARMACOTHERAPY: Hemodynamic Effects of Sildenafil Citrate and Isosorbide Mononitrate in Men with Coronary Artery Disease and Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 407-414.	0.3	16
164	Complications after intracoronary stem cell transplantation in idiopathic dilated cardiomyopathy. International Journal of Cardiology, 2006, 111, 178-179.	0.8	16
165	Catheter-based interventions for acute ischaemic stroke. European Heart Journal, 2016, 37, 3081-3089.	1.0	16
166	Primary angioplasty vs. thrombolysis: the end of the controversy?. European Heart Journal, 2010, 31, 634-636.	1.0	15
167	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart, 2015, 101, 1219-1224.	1.2	15
168	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. European Journal of Preventive Cardiology, 2020, 27, 682-692.	0.8	15
169	Off-pump versus on-pump coronary artery bypass grafting surgery in high-risk patients: PRAGUE-6 trial at 30 days and 1 year. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 263-270.	0.2	15
170	Pharmacodynamic Effect of Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Implantation. BioMed Research International, 2013, 2013, 1-3.	0.9	14
171	Interval From Initiation of Prasugrel toÂCoronary Angiography in PatientsÂWith Nonâ€"ST-Segment ElevationÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2019, 73, 906-914.	1.2	14
172	How to set up an effective national primary angioplasty network: lessons learned from five European countries. EuroIntervention, 2009, 5, 299, 301-309.	1.4	14
173	High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagulation and Fibrinolysis, 2009, 20, 257-262.	0.5	13
174	Optimal pretreatment timing for high load dosing (600Âmg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. International Journal of Cardiology, 2010, 144, 255-257.	0.8	13
175	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 232-244.	1.4	13
176	Acute heart failure registry from high-volume university hospital ED: comparing European and US data. American Journal of Emergency Medicine, 2012, 30, 695-705.	0.7	12
177	ECG in patients with acute heart failure can predict in-hospital and long-term mortality. Internal and Emergency Medicine, 2014, 9, 283-291.	1.0	12
178	A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		12
179	Hyperuricemia treatment in acute heart failure patients does not improve their longâ€term prognosis: A propensity score matched analysis from the AHEAD registry. Clinical Cardiology, 2019, 42, 720-727.	0.7	12
180	An international survey of clinical practice during primary percutaneous coronary intervention for ST-elevation myocardial infarction with a focus on aspiration thrombectomy. EuroIntervention, 2013, 8, 1143-1148.	1.4	12

#	Article	IF	Citations
181	Realâ€<scp>W</scp>orld Safety and Effectiveness Outcomes of a Zotarolimusâ€<scp>E</scp>luting Stent: Final 3â€<scp>Y</scp>ear Report of the <scp>RESOLUTE</scp> International Study. Journal of Interventional Cardiology, 2013, 26, 515-523.	0.5	11
182	Serum Dickkopf-1 signaling and calcium deposition in aortic valve are significantly related to the presence of concomitant coronary atherosclerosis in patients with symptomatic calcified aortic stenosis. Journal of Translational Medicine, 2015, 13, 63.	1.8	11
183	The year in cardiology 2018: acute coronary syndromes. European Heart Journal, 2019, 40, 271-282.	1.0	11
184	Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI : data from a multicentre registry : cardiovascular topic. Cardiovascular Journal of Africa, 2012, 23, 495-500.	0.2	11
185	Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic. Journal of Clinical Medicine, 2021, 10, 24.	1.0	11
186	Effect of papaverine administration on myocardial echocontrast distribution. American Heart Journal, 1987, 114, 1248-1249.	1.2	10
187	Intracoronary transplantation of bone marrow stem cells: background, techniques, and limitations. Country Review Ukraine, 2006, 8, H16-H22.	0.8	10
188	Expert consensus statement of the Czech Society of Cardiology and the Czech Society of Hypertension on catheter-based sympathetic renal denervation procedures (RDN) in the Czech Republic. Cor Et Vasa, 2012, 54, e108-e112.	0.1	10
189	Design and Rationale of the PRAGUEâ€12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation. Clinical Cardiology, 2013, 36, 1-5.	0.7	10
190	Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: Classification tree analysis on data from the Acute Heart Failure Databaseâ€“Main registry. Journal of Critical Care, 2013, 28, 250-258.	1.0	10
191	Predictors of complete arrhythmia free survival in patients undergoing surgical ablation for atrial fibrillation. PRAGUE-12 randomized study sub-analysis. International Journal of Cardiology, 2014, 172, 419-422.	0.8	10
192	One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, e002933.	1.4	10
193	Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?. Cor Et Vasa, 2018, 60, e165-e168.	0.1	10
194	Echocardiographic picture in diabetes mellitus.. International Heart Journal, 1984, 25, 969-977.	0.6	10
195	Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. EuroIntervention, 2016, 12, 465-472.	1.4	10
196	Gender differences in total cholesterol levels in patients with acute heart failure and its importance for short and long time prognosis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 21-22.	0.2	10
197	Acute Myocardial Infarction Complicated by Early Onset of Heart Failure:. Journal of Interventional Cardiology, 2003, 16, 201-208.	0.5	9
198	Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: Data from the Resolute program. International Journal of Cardiology, 2013, 168, 3522-3526.	0.8	9

#	Article	IF	Citations
199	ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. European Heart Journal, 2013, 34, 2073-2073.	1.0	9
200	Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. Cor Et Vasa, 2014, 56, e235-e239.	0.1	9
201	Impact of body mass index on longâ€term clinical outcomes after secondâ€generation drug eluting stent implantation: Insights from the international global <scp>RESOLUTE</scp> program. Catheterization and Cardiovascular Interventions, 2015, 85, 952-958.	0.7	9
202	Transcatheter aortic valve implantation: long-term clinical outcome and valve durability. Expert Review of Medical Devices, 2015, 12, 529-535.	1.4	9
203	Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study. Heart and Vessels, 2016, 31, 841-845.	0.5	9
204	DoubleâEDose Versus StandardâEDose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	1.6	9
205	Prevalence and predictors of coronary artery disease in patients undergoing carotid artery stenting. Coronary Artery Disease, 2019, 30, 204-210.	0.3	9
206	Stable Clinical Outcomes When a Stroke Thrombectomy Program Is Started in an Experienced Cardiology Cath Lab. JACC: Cardiovascular Interventions, 2021, 14, 785-792.	1.1	9
207	Influence of Primary Coronary Intervention on Myocardial Collagen Metabolism and Left Ventricle Remodeling Predicted by Collagen Metabolism Markers. International Heart Journal, 2005, 46, 949-959.	0.5	9
208	Summary of the 2012 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevations. Prepared by the Czech Society of Cardiology. Cor Et Vasa, 2012, 54, e273-e289.	0.1	8
209	Renal Function Assessed Using Cystatin C and Antiplatelet Efficacy of Clopidogrel Assessed Using the Vasodilator-Stimulated Phosphoprotein Index in Patients Having Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 109, 620-623.	0.7	8
210	The use of revascularization strategies in patients with acute coronary syndromes admitted to hospitals without catheterization facilities: Results from the ALERT-CZ registry. Cor Et Vasa, 2013, 55, e207-e211.	0.1	8
211	Corrigendum to: Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 2697-2697.	1.0	8
212	The influence of age on clinical outcomes in patients treated with the resolute zotarolimusâ€eluting stent. Catheterization and Cardiovascular Interventions, 2016, 87, 253-261.	0.7	8
213	Degenerative changes and immune response after transcatheter aortic valve implantation. Comparison with surgical aortic valve replacement. Journal of Cardiology, 2017, 69, 483-488.	0.8	8
214	Bioresorbable scaffold implantation in STEMI patients: 5Âyears imaging subanalysis of PRAGUE-19 study. Journal of Translational Medicine, 2020, 18, 33.	1.8	8
215	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	1.4	8
216	Risk of a coronary event in patients after ischemic stroke or transient ischemic attack. Anatolian Journal of Cardiology, 2021, 25, 152-155.	0.5	8

#	Article	IF	Citations
217	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	1.5	8
218	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 462-473.	1.4	8
219	Variable penetration of primary angioplasty in Europe â€“ what determines the implementation rate?. EuroIntervention, 2012, 8, P18-P26.	1.4	8
220	Direct catheter-based thrombectomy in acute ischaemic stroke performed collaboratively by cardiologists, neurologists and radiologists: the single-centre pilot experience (PRAGUE-16 study). EuroIntervention, 2014, 10, 869-875.	1.4	8
221	Does previous hypertension affect outcome in acute heart failure?. European Journal of Internal Medicine, 2011, 22, 591-596.	1.0	7
222	Clopidogrel up-titration versus standard dose in patients with high residual platelet reactivity after percutaneous coronary intervention: A single-center pilot randomised study. International Journal of Cardiology, 2011, 150, 231-232.	0.8	7
223	THE RELATIONSHIP BETWEEN SHORT AND LONGâ€“TERM ANTIPLATELET THERAPY USE AND STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION WITH THE RESOLUTE ZOTAROLIMUSâ€“ELUTING STENT. Journal of the American College of Cardiology, 2013, 61, E1862.	1.2	7
224	An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current Medical Research and Opinion, 2014, 30, 2193-2205.	0.9	7
225	Acute myocardial infarction complicated by shock: outcome analysis based on initial electrocardiogram. Scandinavian Cardiovascular Journal, 2014, 48, 13-19.	0.4	7
226	Potential role of invariant natural killer T cells in outcomes of acute myocardial infarction. International Journal of Cardiology, 2015, 187, 663-665.	0.8	7
227	"Stent 4 Life" targeting PCI at all who will benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC Working Group on Acute Cardiac Care. EuroIntervention, 2009, 4, 555, 557.	1.4	7
228	Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy. Genetic Testing and Molecular Biomarkers, 2009, 13, 647-650.	0.3	6
229	An embolus in the right atrium caught in the Chiari network and resistant to thrombolysis. Journal of Thrombosis and Thrombolysis, 2010, 30, 114-118.	1.0	6
230	Acute coronary syndromes with ongoing myocardial ischemia (ACS with OMI) versus acute coronary syndromes without ongoing ischemia (ACS without OMI). The new classification of acute coronary syndromes should replace old classification based on ST segment elevation presence or absence-Expert consensus statement of the Czech Society of Cardiology. Cor Et Vasa, 2013, 55, e225-e227.	0.1	6
231	Ischaemic stroke and ST-segment elevation myocardial infarction: fast-track single-stop approach. European Heart Journal, 2015, 36, 2348-2355.	1.0	6
232	Absorb bioresorbable stents for the treatment of coronary artery disease. Expert Review of Medical Devices, 2015, 12, 545-557.	1.4	6
233	Is bivalirudin just an expensive heparin?: TableÂ1. European Heart Journal, 2016, 37, 1321-1324.	1.0	6
234	The importance of time: Time delays in acute stroke. Cor Et Vasa, 2016, 58, e225-e232.	0.1	6

#	Article	IF	Citations
235	Incidence, treatment strategies and outcomes of acute coronary syndrome with and without ongoing myocardial ischaemia: results from the CZECH-3 registry. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 687-694.	0.4	6
236	Czech Republic and low COVID-19 mortality in the heart of Europe: possible explanations. European Heart Journal, 2020, 41, 3876-3879.	1.0	6
237	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart, 2021, 107, 1130-1137.	1.2	6
238	The potential value of histological analysis of thrombi extracted through mechanical thrombectomy during acute ischemic stroke treatment. Anatolian Journal of Cardiology, 2020, 23, 254-259.	0.5	6
239	The impact of age and Killip class on outcomes of primary percutaneous coronary intervention. Insight from the PRAGUE-1 and -2 trials and registry. EuroIntervention, 2007, 2, 481-6.	1.4	6
240	Clinical and radiological factors predicting stroke outcome after successful mechanical intervention in anterior circulation. European Heart Journal Supplements, 2022, 24, B48-B52.	0.0	6
241	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	1.4	6
242	Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vascular Health and Risk Management, 2009, 5, 475.	1.0	5
243	Clopidogrel resistance "Live" ï¿½ the risk of stent thrombosis should be evaluated before procedures. Thrombosis Journal, 2009, 7, 6.	0.9	5
244	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2013, 36, 1-6.	1.0	5
245	Patterns of Longâ€term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the <scp>TIMI</scp>â€38 Coronary Stent Registry. Clinical Cardiology, 2014, 37, 293-299.	0.7	5
246	Technical and safety aspects of renal denervation. Cor Et Vasa, 2014, 56, e228-e234.	0.1	5
247	Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. International Journal of Cardiology, 2016, 203, 708-713.	0.8	5
248	Worse prognosis of realâ€world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAXâ€AHF trial. ESC Heart Failure, 2017, 4, 8-15.	1.4	5
249	LUCAS II Device for Cardiopulmonary Resuscitation in a Nonselective Out-of-Hospital Cardiac Arrest Population Leads to Worse 30-Day Survival Rate Than Manual Chest Compressions. Journal of Emergency Medicine, 2020, 59, 673-679.	0.3	5
250	The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUEâ€17 trial subanalysis. Journal of Cardiovascular Electrophysiology, 2021, 32, 2645-2654.	0.8	5
251	Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions. EuroIntervention, 2015, 11, 650-657.	1.4	5
252	Pericardial Effusion as a Consequence of Acute Myocardial Infarction. Echocardiography, 1999, 16, 317-320.	0.3	4

#	Article	IF	Citations
253	Severe Left Ventricular Systolic Dysfunction is Independently Associated with High On-Clopidogrel Platelet Reactivity. American Journal of Cardiovascular Drugs, 2014, 14, 313-318.	1.0	4
254	Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients â€" Results from PRAGUE-19 study. International Journal of Cardiology, 2016, 209, 20-21.	0.8	4
255	Clinical outcomes of acute ischemic stroke patients treated by direct catheter-based trombectomy depending on their baseline characteristics. Cor Et Vasa, 2018, 60, e30-e34.	0.1	4
256	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	1.4	4
257	The comparison of platelet activity between patients with patent vs. occluded coronary artery bypass grafts. Thrombosis Research, 2007, 120, 523-529.	0.8	3
258	Comparison of cationic propyl gallate and adenosine diphosphate for the meassurement of aspirin effectivity with optical aggregometry. Translational Research, 2007, 150, 246-252.	2.2	3
259	La iniciativa Stent for Life en Europa. Revista Espanola De Cardiologia Suplementos, 2011, 11, 2-5.	0.2	3
260	Stent for Life Initiative: where are we standing and where are we going?. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 48-49.	0.4	3
261	Circulating osteoprotegerin and Dickkopf-1 changed significantly after surgical aortic valve replacement but remained without any significant differences after transcatheter aortic valve implantation. International Journal of Cardiology, 2012, 158, 300-301.	0.8	3
262	Evolving strategies in the management of acute coronary syndromes with oral antiplatelet agents. Cor Et Vasa, 2012, 54, e32-e38.	0.1	3
263	Protocols of antithrombotic therapy in a University Cardiocenter. Cor Et Vasa, 2013, 55, e201-e206.	0.1	3
264	Trends in epidemiology and the treatment of acute coronary syndromes in the Czech Republic: Comparison of the CZECH-1 and CZECH-2 registries. Cor Et Vasa, 2014, 56, e285-e290.	0.1	3
265	Variants in miRNA Regulating Cardiac Growth Are Not a Common Cause of Hypertrophic Cardiomyopathy. Cardiology, 2015, 130, 137-142.	0.6	3
266	Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 282-288.	0.4	3
267	Mechanical circulatory support: harm without benefit? Fascinated by devices, cardiologists may lose common sense. European Heart Journal, 2017, 38, 3535-3537.	1.0	3
268	Endovascular thrombectomy 2020: open issues. European Heart Journal Supplements, 2020, 22, M13-M18.	0.0	3
269	Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe. European Heart Journal Supplements, 2022, 24, B3-B9.	0.0	3
270	Nearâ€normal coronary angiography in a patient, who is entirely asymptomatic 24 years after successful intracoronary thrombolysis for ST elevation myocardial infarction. Followâ€up of the historically first Czech intracoronary thrombolysis patient. Acute Cardiac Care, 2007, 9, 239-242.	0.2	2

#	Article	IF	Citations
271	The Time Has Come for New, More Precise Guidelines in the Treatment of High-Risk Acute Coronary Syndromes With Heparin. Circulation Journal, 2008, 72, 1674-1679.	0.7	2
272	Clopidogrel Before Elective Percutaneous Coronary Intervention. Journal of Clinical Pharmacology, 2010, 50, 373-379.	1.0	2
273	RESISTANCE TO CLOPIDOGREL ASSESSED BY VASP PHOSPHORYLATION IS A NEGATIVE PROGNOSTIC FACTOR IN PATIENTS UNDERGOING ELECTIVE PCI FOR STABLE CORONARY ARTERY DISEASE: ANALYSIS FROM LABORATORY SUBSTUDY OF PRAGUE 8 TRIAL. Journal of the American College of Cardiology, 2010, 55, A98.E926.	1.2	2
274	Platelet-derived chemokines, PF-4 and RANTES, are significantly increased in hemodynamically significant degenerative aortic stenosis. International Journal of Cardiology, 2011, 152, 273-275.	0.8	2
275	Acute myocardial infarction due to the left main coronary artery occlusion: electrocardiograhic patterns, angiographic findings, revascularization and in-hospital outcomes. Cor Et Vasa, 2012, 54, e3-e7.	0.1	2
276	The mortality benefit seen with the newer more potent oral P2Y12 inhibitors prasugrel and ticagrelor over clopidogrel is dependent on the underlying risk: A class effect as suggested by a meta-regression analysis. Cor Et Vasa, 2018, 60, e127-e132.	0.1	2
277	Heart rate as an independent predictor of long term mortality of acute heart failure patients in sinus rhythm according to their ejection fraction: data from the AHEAD registry. European Journal of Internal Medicine, 2020, 78, 88-94.	1.0	2
278	Inter-hospital Transport for Primary Angioplasty Does Not Compromise Left Ventricular Function. International Heart Journal, 2003, 44, 313-322.	0.6	2
279	Acute ischaemic stroke in atrial fibrillation: worse outcomes unrelated to treatment methods. EuroIntervention, 2017, 13, 905-906.	1.4	2
280	Stent thrombosis during and after acute coronary syndromes: patient-related factors and operator-related factors. Anatolian Journal of Cardiology, 2020, 24, 274-279.	0.5	2
281	Left atrial appendage closure â€“ ready for widespread clinical use?. EuroIntervention, 2020, 16, e701-e702.	1.4	2
282	Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease. Expert Review of Medical Devices, 2014, 11, 247-257.	1.4	1
283	Transportation to primary percutaneous coronary intervention, compared with on-site fibrinolysis, is a strong independent predictor of functional status after myocardial infarction: 5-year follow-up of the PRAGUE-2 trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 105-109.	0.4	1
284	Acute Revascularization in ST-Segment-Elevation Myocardial Infarction. Current Atherosclerosis Reports, 2014, 16, 412.	2.0	1
285	Antiplatelet therapy in patients after an acute coronary syndrome. Comparison of the Czech and Slovak Republics. Results of the ATHRO registry. Cor Et Vasa, 2014, 56, e320-e324.	0.1	1
286	Trends in the treatment and outcomes of elderly patients with acute coronary syndrome: Results from the CZECH registries. Cor Et Vasa, 2018, 60, e66-e69.	0.1	1
287	Optical coherence tomography in STEMI with bioresorbable scaffold: possible cause of coronary flow impairment? A sub-study from the Prague 19 trial. Heart and Vessels, 2018, 33, 1282-1287.	0.5	1
288	Revaskularizace myokardu. PerkutÃ¡nnÃ-koronÃ¡rnÃ-intervence a aortokoronÃ¡rnÃ-bypass. Cor Et Vasa, 2011, 53, 3-24.	0.1	1

#	Article	IF	Citations
289	The Bioresorbable Stent in Perspectiveâ€"How Much of an Advance is It?. Interventional Cardiology Review, 2011, 9, 23.	0.7	1
290	When will acute stroke interventions be as widely available as primary PCI?. EuroIntervention, 2017, 13, 1269-1272.	1.4	1
291	Direct transfer of acute stroke patients to angiography suites equipped with flat-detector computed tomography: literature review and initial single-centre experience. European Heart Journal Supplements, 2022, 24, B42-B47.	0.0	1
292	Stroke thrombectomy (± thrombolysis), and not thrombolysis alone, should be the gold standard for stroke treatment. EuroIntervention, 2022, 17, e1367-e1368.	1.4	1
293	THE TIME HAS COME FOR NEW, MORE PRECISE GUIDELINES IN THE TREATMENT OF HIGH RISK ACUTE CORONARY SYNDROMES WITH HEPARIN. Chest, 2007, 132, 545A.	0.4	0
294	TCT-639 Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Vessels â‰¥2.5 mm Diameter. Journal of the American College of Cardiology, 2012, 60, B186.	1.2	0
295	Outcomes of patients hospitalized for suspected acute coronary syndrome, in whom the diagnosis was not confirmed: Results from the CZECH-1 and CZECH-2 registries. Cor Et Vasa, 2015, 57, e1-e5.	0.1	0
296	Reply. Journal of the American College of Cardiology, 2015, 65, 1718-1719.	1.2	0
297	How many years it will take to implement the new stroke guidelines for the benefit of all suitable patients with acute ischemic stroke in Europe?. Cor Et Vasa, 2016, 58, e212-e214.	0.1	0
298	Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study. PLoS ONE, 2017, 12, e0177519.	1.1	0
299	History of cardiovascular research at the Charles University. European Heart Journal Supplements, 2020, 22, F1-F5.	0.0	0
300	Current cardiovascular research at the Charles University: the â€˜PRAGUEâ€™ trials and beyond. European Heart Journal Supplements, 2020, 22, F6-F13.	0.0	0
301	The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUEâ€“18 substudy. International Journal of Cardiology, 2020, 319, 1-6.	0.8	0
302	Otto Klein from Prague University Hospital performed the world first diagnostic cardiac catheterization in 11 Czech patients in 1929. European Heart Journal, 2020, 41, 1323-1325.	1.0	0
303	Jiri Widimsky MD. European Heart Journal, 2021, 42, 1285-1286.	1.0	0
304	Cellular therapy of coronary heart disease: a review of concepts, limitations, prospects. Part Two. Stem cells, prospects of cullular therapy. Cor Et Vasa, 2006, 48, 234-241.	0.1	0
305	Left ventricular remodelling adaptation or maladaptation?. Cor Et Vasa, 2006, 48, 441-446.	0.1	0
306	Treatment of ST elevation acute myocardial infarction in Europe. Cor Et Vasa, 2010, 52, 22-23.	0.1	0

#	Article	IF	Citations
307	Measuring of platelet activity and efficacy of antiplatelet therapy. Cor Et Vasa, 2010, 52, 15-20.	0.1	0
308	Aspirin resistance after coronary artery bypass grafting. Cor Et Vasa, 2010, 52, 52-58.	0.1	0
309	Electrocardiogram changes due to myocardial infarction in a patient with selective His bundle pacing. Kardiologia Polska, 2019, 77, 237-237.	0.3	0
310	The relationship between symptom onset-to-needle time and ischemic outcomes in patients with acute myocardial infarction treated with primary PCI. Journal of Cardiology, 2022, 79, 626-633.	0.8	0